By selecting the Yes option, Leave Amgen.co.uk option, you understand that you are leaving the corporate page of Amgen UK and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Europe is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Europe. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
The quicDNA project, which aims to enhance healthcare in Wales by accelerating lung cancer diagnosis and treatment through innovative liquid biopsy (ctDNA) testing, has already been celebrated for its transformative impact since starting back in March 2023.
Liquid biopsies, less invasive than surgical biopsies, offer early diagnostic genomic analysis, enabling faster treatment initiation. This two-year evaluation involves multiple Welsh Health Boards and key partners, including the All-Wales Medical Genomic Services (AWMGS) and industry partners including Amgen.
The innovative collaborative approach of the project has been recognised by the Welsh Healthcare System, having picked up multiple awards at prestigious healthcare events, including ‘New Ways of Working’ and ‘Overall Winner’ at the Advancing Healthcare Awards (AHA) Wales 2023.
The project's success is bolstered by significant fundraising efforts from patient advocate Craig Maxell, who has raised over £1 million to date - Watch Craig’s incredible story here: